Skip to main content
Ronald Crystal, MD, Pulmonology

Ronald G Crystal MD

Pleural Disease


The Bruce Webster Professor of Internal Medicine. Professor of Medicine. Professor of Genetic Medicine. Attending Physician, NewYork-Presbyterian Hospital.

Overview of  Dr. Crystal

Dr. Ronald Crystal is a pulmonologist and is affiliated with New York-Presbyterian Hospital. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 58 years. Dr. Crystal accepts several types of health insurance, listed below. He is one of 278 doctors at New York-Presbyterian Hospital who specialize in Pulmonology. He has more than 100 publications and over 500 citings.

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Residency, Internal Medicine, 1973 - 1973
  • Mass General Brigham/Massachusetts General Hospital
    Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1968 - 1970
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 1968

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1973 - Present
  • NY State Medical License
    NY State Medical License 1993 - 2028
  • FL State Medical License
    FL State Medical License 2017 - 2022
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Pulmonary Disease
    American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Articles Disease Characteristics and Progression in Patients with Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease: An Observational Cohort Study  
    Barry Kosofsky, Kaleb Yohay, Ronald G Crystal, ScienceDirect
  • Gene Therapy for C1 Esterase Inhibitor Deficiency in a Murine Model of Hereditary Angioedema  
    Ronald G Crystal, Stephen M Kaminsky, Allergy

Lectures

  • Biologic Therapeutics Seminar Series - Developing Viral-based Therapies Against Brain Tumors 
    Washington University School of Medicine, Saint Louis, Missouri - 4/25/2012
  • Biologic Therapeutic Seminar Series - Treatment of B Cell Malignancies & Mesothelioma with Recombinant Immunotoxins 
    Washington University School of Medicine, Saint Louis, Missouri - 3/21/2012
  • Biologic Therapeutics Seminar Series - In Vivo Gene Transfer for Genetic Disease: Progress & Challenges 
    Washington University School of Medicine, Saint Louis, Missouri - 1/25/2012

Press Mentions

  • XyloCor Makes Significant Progress in Gene Therapy for Cardiovascular Disease
    XyloCor Makes Significant Progress in Gene Therapy for Cardiovascular DiseaseJanuary 30th, 2023
  • A Promising Trial Targets a Genetic Risk for Alzheimer’s
    A Promising Trial Targets a Genetic Risk for Alzheimer’sDecember 2nd, 2022
  • WCM-Q Research Reveals Metabolic Processes Underpinning Type 2 Diabetes, Complications
    WCM-Q Research Reveals Metabolic Processes Underpinning Type 2 Diabetes, ComplicationsMay 19th, 2022

Grant Support

  • Gene Therapy for APOE4 Homozygous Alzheimer's DiseaseWEILL MEDICAL COLL OF CORNELL UNIV2026–2028
  • Gene Therapy for Alpha 1-Antitrypsin DeficiencyWEILL MEDICAL COLL OF CORNELL UNIV2024–2028
  • Ancillary SOURCE Study: Characterization of Small Airway Basal Cell Biology in Early COPDWEILL MEDICAL COLL OF CORNELL UNIV2023–2027
  • Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency in Post-menopausal East Asian WomenENYX THERAPEUTICS, LLC2020–2027
  • Gene Therapy-mediated Angiogenesis to Enhance Survival of Transplanted FatENYX THERAPEUTICS, LLC2024–2026

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    Great West PPO
    Healthfirst New York
    HIP of New York - Select PPO
    MagnaCare PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: